A clinical-stage biopharmaceutical company focused on developing oncological therapies to improve patient outcomes.

Carrick Therapeutics

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour.
Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Woodford Investment Management

Lightstone Ventures

Cambridge Innovation Capital

Evotec

University of Cambridge Enterprise

ARCH Venture Partners

Google Ventures

Pfizer

Revelation Partners

Rosetta Capital

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

https://lnkd.in/eTajEtpM

Delighted to announce a First Patient Dosed in our Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer. 

https://lnkd.in/e8deVH6g

Great interview on Oncology Tube with our CMO Stuart McIntosh talking about our ongoing Phase 2 study SUMIT-ELA, combining samuraciclib and elacestrant in patients with CDK4/6i resistant HR+,HER2- metastatic breast cancer in collaboration with Menarini. 

https://lnkd.in/ezt5ZqWW

Delighted to announce US FDA clearance of our IND for CT7439, a First In Class Inhibitor of CDK12/13. Carrick's second therapeutic candidate which further strengthens our oncology pipeline.
https://lnkd.in/e7WuT_9v

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Jul 27, 2024 2:22 AM	c335cbd5
public peers	general	Jul 26, 2024 4:13 AM	169cf2d7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 26, 2024 2:15 PM	21a8f1c9
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Jul 26, 2024 4:13 AM	00fa3d9d
news basic	general	Jul 26, 2024 4:13 AM	bdb0549d
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:CARRICKTHERAPEUTICS

Carrick Therapeutics